These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Practical guidance for mismatch repair-deficiency testing in endometrial cancer. Stelloo E; Jansen AML; Osse EM; Nout RA; Creutzberg CL; Ruano D; Church DN; Morreau H; Smit VTHBM; van Wezel T; Bosse T Ann Oncol; 2017 Jan; 28(1):96-102. PubMed ID: 27742654 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic Accuracy of Immunohistochemistry for Mismatch Repair Proteins as Surrogate of Microsatellite Instability Molecular Testing in Endometrial Cancer. Raffone A; Travaglino A; Cerbone M; Gencarelli A; Mollo A; Insabato L; Zullo F Pathol Oncol Res; 2020 Jul; 26(3):1417-1427. PubMed ID: 32377987 [TBL] [Abstract][Full Text] [Related]
5. Comparison of Methods for Testing Mismatch Repair Status in Endometrial Cancer. Mendiola M; Heredia-Soto V; Ruz-Caracuel I; Baillo A; Ramon-Patino JL; Escudero FJ; Miguel M; Pelaez-Garcia A; Hernandez A; Feliu J; Hardisson D; Redondo A Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833916 [TBL] [Abstract][Full Text] [Related]
6. A retrospective study of consistency between immunohistochemistry and polymerase chain reaction of microsatellite instability in endometrial cancer. Wang C; Kuang W; Zeng J; Ren Y; Liu Q; Sun H; Feng M; Liang D PeerJ; 2023; 11():e15920. PubMed ID: 37663290 [TBL] [Abstract][Full Text] [Related]
7. Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker. Backes FJ; Haag J; Cosgrove CM; Suarez A; Cohn DE; Goodfellow PJ Cancer; 2019 Feb; 125(3):398-405. PubMed ID: 30561762 [TBL] [Abstract][Full Text] [Related]
8. Clinicopathological features of 50 mismatch repair (MMR)-deficient endometrial carcinomas, tested by immunohistochemistry: A single institutional feasibility study, India. Rekhi B; Menon S; Deodhar KK; Ghosh J; Chopra S; Maheshwari A Ann Diagn Pathol; 2020 Aug; 47():151558. PubMed ID: 32619922 [TBL] [Abstract][Full Text] [Related]
9. Lynch Syndrome in Thai Endometrial Cancer Patients. Manchana T; Ariyasriwatana C; Triratanachat S; Phowthongkum P Asian Pac J Cancer Prev; 2021 May; 22(5):1477-1483. PubMed ID: 34048176 [TBL] [Abstract][Full Text] [Related]
10. [Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma]. Liu Y; Wang YX; Sun XJ; Ting X; Wu R; Liu XD; Liu CR Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):755-765. PubMed ID: 37849256 [No Abstract] [Full Text] [Related]
11. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome. Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759 [TBL] [Abstract][Full Text] [Related]
12. The Significance of Mismatch Repair Deficiency in Young Patients With Endometrial Cancer. Chu MM; Liu SS; Tam KF; Ip PP; Cheung AN; Ngan HY Int J Gynecol Pathol; 2015 Sep; 34(5):403-10. PubMed ID: 26262451 [TBL] [Abstract][Full Text] [Related]
13. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer]. Jin W; Wang LQ; Liu Y; Liu AJ Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020 [No Abstract] [Full Text] [Related]
14. Somatic Sequencing and Microsatellite Instability Results From Mismatch Repair-deficient Endometrial Carcinoma Patients Without Lynch Syndrome ("Lynch-like" tumors): Implications for Heritable Cancer Screening, Molecular Prognostication, and Immunotherapeutic Vulnerability. Makia NL; Thomas M; Ring KL; Moskaluk CA; Mills AM Am J Surg Pathol; 2023 Aug; 47(8):878-888. PubMed ID: 37248962 [TBL] [Abstract][Full Text] [Related]
15. Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic Cancers. Noh JJ; Kim MK; Choi MC; Lee JW; Park H; Jung SG; Joo WD; Song SH; Lee C Cancer Res Treat; 2022 Oct; 54(4):1200-1208. PubMed ID: 34902958 [TBL] [Abstract][Full Text] [Related]
16. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. McConechy MK; Talhouk A; Li-Chang HH; Leung S; Huntsman DG; Gilks CB; McAlpine JN Gynecol Oncol; 2015 May; 137(2):306-10. PubMed ID: 25636458 [TBL] [Abstract][Full Text] [Related]
17. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors. Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238 [TBL] [Abstract][Full Text] [Related]
18. [Correlation between mismatch-repair protein expression and clinicopathologic features in 658 colorectal cancers]. Hu XR; Xu C; Kang Y; Wang T; Zhang Y; Yang XH Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):827-833. PubMed ID: 30423605 [No Abstract] [Full Text] [Related]
19. Peritumoral granulomatous reaction in endometrial carcinoma: association with DNA mismatch repair protein deficiency, particularly loss of PMS2 expression. Stewart CJR; Pearn A; Pachter N; Tan A Histopathology; 2018 Sep; 73(3):428-437. PubMed ID: 29710374 [TBL] [Abstract][Full Text] [Related]
20. Identification of HNPCC by molecular analysis of colorectal and endometrial tumors. Vasen HF; Hendriks Y; de Jong AE; van Puijenbroek M; Tops C; Bröcker-Vriends AH; Wijnen JT; Morreau H Dis Markers; 2004; 20(4-5):207-13. PubMed ID: 15528786 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]